13 recruiting, 5 not yet recruiting, 2 completed, 2 unknown. 26 Phase 2, 3 Phase 1, 2 Phase 3.
Follow CAPOX: new trials by email Literature Review of CAPOX trials Research Report on CAPOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers Zolbetuximab, mFOLFOX6, CAPOX - Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Midhun Malla | 32 | 2026-11-01 | 2026-11-02 |
| Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Serplulimab, CAPOX, Bevacizumab - Locally Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Xijing Hospital | 85 | 2026-09-01 | 2026-09-15 |
| Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM SCRT, Retlirafusp alfa Injection, Bevacizumab - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 60 | 2026-07-30 | 2026-09-22 |
| KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer KRC-01 (KORTUC), Radiotherapy, Capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 24 | 2026-07-01 | 2026-06-02 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) Pumitamig, Folfox, Capox - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 690 | 2026-03-13 | 2026-11-05 |
| A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma ATG-022, pembrolizumab/KEYTRUDA®, CAPOX - Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Antengene Biologics Limited | 132 | 2026-02-27 | 2026-07-29 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 990 | 2025-12-31 | 2026-10-23 |
| SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer SIB-SCRT, CAPOX, Immunotherapy - Rectal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 37 | 2025-12-20 | 2025-12-22 |
| SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox - Rectal Cancer, Advanced Stage Colorectal Cancer | Phase 2 | Recruiting | Shandong Provincial Hospital | 208 | 2025-09-12 | 2025-12-16 |
| SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer Short-Course Radiotherapy, Fruquintinib, Tislelizumab - Rectal Neoplasms, Rectal Cancer, Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 50 | 2025-09-11 | 2026-10-22 |
| Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer LCRT, SCRT, CAPOX - Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 138 | 2025-08-01 | 2025-09-04 |
| Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) Capecitabine, Camrelizumab, CAPOX - Locally Advanced Rectal Cancer | Phase 2 | Suspended | Hebei Medical University Fourth Hospital | 90 | 2025-07-01 | 2026-07-31 |
| PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer SHR1701, SHR2554, CAPOX - Advanced Gastric Cancer, SHR1701 | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 78 | 2025-06-15 | 2026-09-01 |
| Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2 - Stage I Colon Cancer, Stage II Colon Cancer | Phase 2 | Recruiting | Baylor College of Medicine | 28 | 2025-06-15 | 2025-05-25 |
| Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Sintilimab, Short-course radiotherapy, Long-course concurrent chemoradiotherapy - Locally Advanced Rectal Cancer (LARC) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 228 | 2025-06-01 | 2025-06-26 |
| Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） radiotherapy, CAPOX, Capecitabine - Colon Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 128 | 2025-05-15 | 2026-08-03 |
| Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody) - Rectal Cancer | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 29 | 2024-07-19 | 2024-12-18 |
| Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer split-course hypofraction radiotherapy, CAPOX, Envafolimab - Rectal Cancer | Phase 2 | Not yet recruiting | 池畔 | 72 | 2023-08-15 | 2023-08-01 |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) Spevatamig (PT886), Paclitaxel, Gemcitabine - Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 350 | 2023-03-15 | 2026-09-28 |
| Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma Pembrolizumab, Olaparib, mFOLFOX-6 - Esophagogastric Adenocarcinoma | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 31 | 2022-09-15 | 2025-02-20 |
Showing 20 of 26. Sign in to see all of them.
Rectal Neoplasms (9) · Colorectal Neoplasms (5) · Colonic Neoplasms (4) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Neoplasm, Residual (1) · Neoplastic Cells, Circulating (1)
Bristol-Myers Squibb (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Hebei Medical University Fourth Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Amgen (1) · Antengene Biologics Limited (1) · Baylor College of Medicine (1) · Canadian Cancer Trials Group (1) · Fudan University (1) · Fundación para la Investigación del Hospital Clínico de Valencia (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · IFOM ETS - The AIRC Institute of Molecular Oncology (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Midhun Malla (1) · Phanes Therapeutics (1)
China (15) · United States (8) · Spain (4) · Canada (3) · France (3) · Germany (3) · Italy (3) · Japan (3) · South Korea (3) · Argentina (2) · Australia (2) · Brazil (2) · Chile (2) · India (2) · Mexico (2)
Atif Iqbal, MD (1) · Carl Brown (1) · Changqing Jing, Professor (1) · Fengpeng Wu (1) · Georg Martin Haag, PD Dr. (1) · Hagen Kennecke (1) · Jing Jin, M.D. (1) · Kaixiong Tao, MD (1) · Liu Hong (1) · Michael S Lee, MD (1) · Midhun Malla, MD, MS (1) · Pan Chi, MD (1)
2025 (3), 2019 (1)